drugset / Trial / NCT06791187

A Study in Healthy People to Test Whether BI 1291583 Influences the Amount of Dabigatran in the Body

NCT06791187

Phase 1 Completed 14 enrolled Boehringer Ingelheim
NaCrossoverOpen-labelTreatment

Summary

The main objective of this trial is to investigate the effect of a single dose of BI 1291583 on the pharmacokinetics of a single dose of dabigatran, an efflux transporter P-glycoprotein (P-gp) substrate.

Timeline

Start
2025-01-23
Primary completion
2025-02-21
Completion
2025-03-27

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 1291583 Unknown
Subject Dabigatran etexilate Unknown Oral

Indications

No indication recorded.